# Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1

> **NCT02600429** · PHASE3 · TERMINATED · sponsor: **ReGenTree, LLC** · enrollment: 18 (actual)

## Conditions studied

- Neurotrophic Keratopathy

## Interventions

- **DRUG:** RGN-259
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02600429
- **Lead sponsor:** ReGenTree, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-17
- **Primary completion:** 2019-11-20
- **Final completion:** 2020-03-09
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02600429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02600429, "Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02600429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*